Regulatory and ClinicalSep 9, 2025 · 7:59pm ET
PMVPPMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Announces Interim Data from Phase 2 PYNNACLE Trial for Rezatapopt
The trial focuses on patients with advanced solid tumors and a TP53 Y220C mutation.
Regulatory and ClinicalSep 9, 2025 · 7:59pm ET
PMVPPMV Pharmaceuticals, Inc.+98.7%
PMV Pharmaceuticals Announces Interim Data from Phase 2 PYNNACLE Trial for Rezatapopt